<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hypermethylation of CpG islands is the most well defined epigenetic change in <z:hpo ids='HP_0002664'>neoplasia</z:hpo> and plays an important role in the inactivation or silencing of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> related genes </plain></SENT>
<SENT sid="1" pm="."><plain>DLX genes (1-7), with large CpG islands in their 5' region, are implicated in a number of processes among which haematopoiesis </plain></SENT>
<SENT sid="2" pm="."><plain>They are characterized by highly dynamic spatio-temporal expression and supposed to be involved in resistance to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of several <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) hypermethylation is a common phenomenon frequently associated with poor prognosis in specific genetic childhood <z:hpo ids='HP_0001909'>leukemia</z:hpo> subgroups </plain></SENT>
<SENT sid="4" pm="."><plain>These data together with the presence of large CpG islands in the up-stream regions of the DLX genes make them attractive candidates for methylation regulated gene expression and <z:hpo ids='HP_0001909'>leukemia</z:hpo> related aberrancies </plain></SENT>
<SENT sid="5" pm="."><plain>To validate the role of DLX genes in paediatric <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> cells, we studied two cell lines and two groups of patients with paediatric chromosomal rearrangements: MLL-AF4 and <z:chebi fb="18" ids="30182">TEL</z:chebi>-AML1, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Analysis of methylation and gene expression patterns of DLX3 in 64 specimens of B-lineage ALL revealed that DLX3 presents aberrant methylation in paediatric <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> patients </plain></SENT>
<SENT sid="7" pm="."><plain>In vitro experiments with 5-Aza-2'dC on <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines, confirmed by Western blot analysis, indicated that the methylation of DLX3 CpG islands has a functional role and interferes with the DLX3 gene and DLX3 protein expression in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>Importantly, hypermethylation of DLX3 significantly reduces its expression in MLL-AF4 rearranged <z:hpo ids='HP_0001909'>leukemias</z:hpo> while methylation is almost absent in <z:chebi fb="18" ids="30182">TEL</z:chebi>-AML1 positive ALL specimens </plain></SENT>
<SENT sid="9" pm="."><plain>These results show that differential DLX3 methylation could be a new epigenetic marker for genotypic B-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> subgroup with high-risk features </plain></SENT>
</text></document>